Phase I clinical trial of the 2nd generation proteasome inhibitor NPI-0052 in patients with advanced malignancies with a CLL RP2D

A. Townsend, P. Padrik, P. Mainwaring, T. Price, L. Catley, A. Longenecker, M. A. Palladino, G. K. Lloyd, M. A. Spear, M. Millward

Research output: Contribution to journalAbstract/Meeting Abstractpeer-review

1 Citation (Web of Science)
Original languageEnglish
Pages (from-to)74-74
Number of pages1
JournalEuropean Journal of Cancer Supplements
Volume6
Issue number12
DOIs
Publication statusPublished - Oct 2008
Event20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - Geneva, Switzerland
Duration: 21 Oct 200824 Oct 2008

Cite this